...Dorzagliatin sinogliatin. It began a collaboration with Chiesi Farmaceutici S.p.A....

...Plus: management moves at Phagelux, Chiesi, Kanova and Oyster Point By Danielle Golovin, Staff Writer David Ricks has...
...Zwinski is transitioning to general manager and CEO of Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici S.p.A....
...effective Jan. 1. Zwinski was SVP of sales and head of the cardiovascular business unit at Chiesi.Kanova...

...this year for $21 billion.Arix and Sofinnova Ventures co-led VelosBio’s series A round, investing alongside Pappas, Chiesi...

...metabolic disorders. On Tuesday, it partnered with Chiesi Farmaceutici S.p.A....

...By  Karen Tkach Tuzman, Associate Editor Moderna’s deals with Vertex and Chiesi Group highlight the company’s...
...Inc. (NASDAQ:VRTX), this time focused on editing the CFTR gene, and initiated a collaboration with Chiesi Farmaceutici S.p.A....
...received $20 million in upfront cash and was eligible for $275 million in total milestones.From Chiesi...

...schedule in about 90 days.Priority Review for Fabry, hypercholesterolemia therapiesProtalix BioTherapeutics Inc. (Tel Aviv:PLX; NYSE-A:PLX) and partner Chiesi Farmaceutici S.p.A....

...Ltd. (Tokyo:4502; NYSE:TAK) market Glassia, an IV formulation of AAT, to treat AAT deficiency. Kamada, Chiesi Farmaceutici S.p.A....

...Existing investors joining them were Arrowmark Partners, Berkeley Catalyst Fund, BVF Partners, Pappas Capital & Chiesi...

...of marketed hemostasis, cardiovascular and infectious disease assets in separate transactions with Mallinckrodt plc (NYSE:MNK), Chiesi Farmaceutici S.p.A....

...Kasei Pharma Corp. and Mission Bay Capital also participated, as did existing investors Sanderling and Chiesi...
...NASDAQ:BMRN) and Raptor Pharmaceutical Corp. co-founder Chris Starr. Glycomine raised $12 million from Sanderling and Chiesi...